| detailed description | ICD-O3 code |
|---|
| Myeloproliferative neoplasms | |
Chronic myelogenous leukaemia, BCR-ABL1 positive | 9975/3 |
Chronic neutrophilic leukaemia | 9963/3 |
Polycythaemia vera | 9950/3 |
Primary myelofibrosis | 9961/3 |
Essential thrombocythaemia | 9962/3 |
Chronic eosinophilic leukaemia, NOS | 9964/3 |
Cutaneous mastocytosis | 9740/3 |
Systemic mastocytosis | 9741/3 |
Mast cell leukaemia | 9742/3 |
Mast cell sarcoma | 9740/3 |
Extracutaneous mastocytoma | 9740/1 |
Myeloproliferative neoplasm, unclassifiable | 9975/3 |
| Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 | |
Myeloid and lymphoid neoplasms with PDGFRA rearrangement | 9965/3 |
Myeloid and lymphoid neoplasms with PDGFRB rearrangement | 9966/3 |
Myeloid and lymphoid neoplasms with FGFR1 rearrangement | 9967/3 |
| Myelodysplastic/myeloproliferative neoplasms | |
Chronic myelomonocytic leukaemia | 9945/3 |
Atypical chronic myeloid leukaemia, BCR-ABL1 negative | 9876/3 |
Juvenile myelomonocytic leukaemia | 9946/3 |
Myelodysplastic/myeloproliferative neoplasm, unclassifiable | 9975/3 |
Refractory anemia with ring sideroblasts associated with marked thrombocytosis | 9982/3 |
| Myelodysplastic syndromes | |
Refractory anemia | 9980/3 |
Refractory neutropenia | 9991/3 |
Refractory thrombocytopemia | 9992/3 |
Refractory anaemia with ring sideroblasts | 9982/3 |
Refractory cytopenia with multilineage dysplasia | 9985/3 |
Refractory anaemia with excess blasts | 9983/3 |
Myelodysplastic syndrome with isolated del(5q) | 9986/3 |
Myelodysplastic syndrome, unclassifiable | 9989/3 |
Childhood myelodysplastic syndrome | NS |
Refractory cytopenia of childhood | 9985/3 |
| Acute myeloid leukaemia (AML) and related precursor neoplasms | |
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 9896/3 |
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | 9871/3 |
Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA | 9866/3 |
AML with t(9;11)(p22;q23); MLLT3-MLL | 9897/3 |
AML with t(6;9)(p23;q34); DEK-NUP214v | 9865/3 |
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 | 9869/3 |
AML (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1 | 9911/3 |
AML with mutated NPM1 | 9861/3 |
AML with mutated CEBPA | 9861/3 |
AML with myelodysplasia-related changes | 9895/3 |
Therapy-related myeloid neoplasms | 9920/3 |
Acute myeloid leukaemia, NOS | 9861/3 |
AML with minimal differentiation | 9872/3 |
AML without maturation | 9873/3 |
AML with maturation | 9874/3 |
Acute myelomonocytic leukaemia | 9867/3 |
Acute monoblastic and monocytic leukaemia | 9891/3 |
Acute erythroid leukaemia | 9840/3 |
Acute megakaryoblastic leukaemia | 9910/3 |
Acute basophilic leukaemia | 9870/3 |
Acute panmyelosis with myelofibrosis | 9931/3 |
Myeloid sarcoma | 9872/3 |
Transient abnormal myelopoiesis | 9898/1 |
Myeloid leukaemia associated with Down syndrome | 9898/3 |
Blastic plasmacytoid dendritic cell neoplasm | 9727/3 |
| Acute leukaemias of ambiguous lineage | |
Acute undifferentiated leukaemia | 9801/3 |
Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 | 9806/3 |
Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged | 9807/3 |
Mixed phenotype acute leukaemia, B/myeloid, NOS 152 | 9808/3 |
Mixed phenotype acute leukaemia, T/myeloid, NOS 153 | 9809/3 |
Mixed phenotype acute leukaemia, NOS - rare types | NS |
Other ambiguous lineage leukaemias | NS |
Natural killer (NK)-cell lymphoblastic leukaemia/lymphoma | NS |
| Precursor lymphoid neoplasms | |
B lymphoblastic leukaemia/lymphoma, NOS | 9811/3 |
B lymphoblastic leukaemia/lymphoma with t(9:22)(q34;q11.2); BCR-ABL1 | 9812/3 |
B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged | 9813/3 |
B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | 9814/3 |
B lymphoblastic leukaemia/lymphoma with hyperdiploidy | 9815/3 |
B lymphoblastic leukaemia/lymphoma with hypodiploidy (Hypodiploid ALL) | 9816/3 |
B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH | 9817/3 |
B lymphoblastic leukaemia/lymphoma with t(1;19) (q23;p13.3); E2A-PBX1(TCF3-PBX1) | 9818/3 |
T lymphoblastic leukaemia/lymphoma | 9837/3 |
| Mature B-cell neoplasms | |
Chronic lymphocytic leukaemia /small lymphocytic lymphoma | 9823/3 |
B-cell prolymphocytic leukaemia | 9833/3 |
Splenic marginal zone lymphoma | 9689/3 |
Hairy cell leukaemia | 9940/3 |
Splenic B-cell lymphoma/leukaemia, unclassifiable | 9591/3 |
Splenic diffuse red pulp small B-cell lymphoma | 9591/3 |
Hairy cell leukaemia-variant | 9591/3 |
Lymphoplasmacytic lymphoma | 9671/3 |
Waldenstrom macroglobulinemia | 9761/3 |
Heavy chain diseases | 9762/3 |
Gamma heavy chain disease | 9762/3 |
Mu heavy chain disease | 9762/3 |
Alpha heavy chain disease | 9762/3 |
Plasma cell neoplasms | - |
Monoclonal gammopathy of undetermined significance (MGUS) | 9765/1 |
Plasma cell myeloma / Multiple myeloma | 9732/3 |
Solitary plasmacytoma of bone | 9731/3 |
Extraosseous plasmacytoma | 9734/3 |
Monoclonal immunoglobulin deposition diseases | - |
Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma) | 9699/3 |
Nodal marginal zone lymphoma | 9699/3 |
Paediatric nodal marginal zone lymphoma | 9699/3 |
Follicular lymphoma | 9690/3 |
Paediatric follicular lymphoma | 9690/3 |
Primary cutaneous follicle centre lymphoma | 9597/3 |
Mantle cell lymphoma | 9673/3 |
Diffuse large B-cell lymphoma (DLBCL), NOS | 9680/3 |
T cell/histiocyte-rich large B-cell lymphoma | 9688/3 |
Primary DLBCL of the CNS | 9680/3 |
Primary cutaneous DLBCL, leg type | 9680/3 |
EBV positive DLBCL of the elderly | 9680/3 |
DLBCL associated with chronic inflammation | 9680/3 |
Lymphomatoid granulomatosis | 9766/3 |
Primary mediastinal (thymic) large B-cell lymphoma | 9679/3 |
Intravascular large B-cell lymphoma | 9712/3 |
ALK positive large B-cell lymphoma | 9737/3 |
Plasmablastic lymphoma | 9735/3 |
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease | 9738/3 |
Primary effusion lymphoma | 9678/3 |
Burkitt lymphoma | 9687/3 |
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma | 9680/3 |
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma | 9596/3 |
| Mature T- and NK-cell neoplasms | |
T-cell prolymphocytic leukaemia | 9834/3 |
T-cell large granular lymphocytic leukaemia | 9831/3 |
Chronic lymphoproliferative disorder of NK cells | 9831/3 |
Aggressive NK cell leukaemia | 9948/3 |
Systemic EBV+ T-cell lymphoproliferative disease of childhood | 9724/3 |
Hydroa vacciniforme-like lymphoma | 9725/3 |
Adult T-cell leukaemia/lymphoma | 9827/3 |
Extranodal NK/T-cell lymphoma, nasal type | 9719/3 |
Enteropathy-associated T-cell lymphoma | 9717/3 |
Hepatosplenic T-cell lymphoma | 9716/3 |
Subcutaneous panniculitis-like T-cell lymphoma | 9708/3 |
Mycosis fungoides | 9700/3 |
Sèzary syndrome | 9701/3 |
Lymphomatoid papulosis | 9718/1 |
Primary cutaneous anaplasic large cell lymphoma | 9718/3 |
Primary cutaneous peripheral T-cell lymphomas, rare subtypes | |
Primary cutaneous gamma-delta T-cell lymphoma | 9726/3 |
Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma | 9709/3 |
Primary cutaneous CD4 positive small/medium T-cell lymphoma | 9709/3 |
Peripheral T-cell lymphoma, NOS | 9702/3 |
Angioimmunoblastic T-cell lymphoma | 9705/3 |
Anaplastic large cell lymphoma, ALK positive | 9714/3 |
Anaplastic large cell lymphoma, ALK negative | 9702/3 |
| Hodgkin lymphoma | |
Nodular lymphocyte predominant Hodgkin lymphoma | 9659/3 |
Classical Hodgkin lymphoma | 9650/3 |
Nodular sclerosis classical Hodgkin lymphoma | 9663/3 |
Mixed cellularity classical Hodgkin lymphoma | 9652/3 |
Lymphocyte-rich classical Hodgkin lymphoma | 9651/3 |
Lymphocyte-depleted classical Hodgkin lymphoma | 9653/3 |
| Immunodeficiency-associated lymphoproliferative disorders | |
Lymphoproliferative diseases associated with primary immune disorders | NS |
Lymphomas associated with HIV infection | NS |
Plasmatic hyperplasia | 9971/1 |
Infectious mononucleosis-like PTLD | 9971/1 |
Polymorphic PTLD | 9971/3 |
Monomorphic PTLD (B- and T/NK-cell types, classified according to the leukemia/lymphomato which they correspond) | - |
Classical Hodgkin lymphoma type PTLD | - |
| Histiocytic and dendritic cell neoplasms | |
Histiocytic sarcoma | 9755/3 |
Langerhans cell histiocytosis | 9751/3 |
Langerhans cell sarcoma | 9756/3 |
Interdigitating dendritic cell sarcoma | 9757/3 |
Follicular dendritic cell sarcoma | 9758/3 |
Intermediate dendritic cell tumour | 9759/3 |
Disseminated juvenile xanthogranuloma | NS |
